๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Two different lymph node metastatic patterns of a prostatic cancer

โœ Scribed by Hiroshi Saitoh; Ken-Ichiro Yoshida; Yutaka Uchijima; Nobuyuki Kobayashi; Junji Suwata; Shigeyoshi Kamata

Publisher
John Wiley and Sons
Year
1990
Tongue
English
Weight
360 KB
Volume
65
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

โœฆ Synopsis

Among 753 autopsy prostatic cancer cases with a metastasis, 476 (63%) had a lymph node metastasis, whereas 277 (37%) did not. Two different lymph node metastatic patterns were observed: Type 1, combined metastasis involving the pelvic and paraaortic lymph nodes; and Type 2, metastasis to the paraaortic lymph nodes, but not to the pelvic lymph nodes. Type 1 metastasis cases showed a significantly more frequent metastasis to the bladder and rectum, and a less frequent metastasis to the lungs and liver. Hydronephrosis occurred more frequently (P < 0.01) in the Type 1. Furthermore, in the Type 1 cases the lymph node metastasis appeared to be continuously invasive, but in the Type 2 cases, metastasis appeared to be the skip type or some metastases may have spread via the vertebral vein bypass route and may have been associated with a hematogenous metastasis.

๐Ÿ“œ SIMILAR VOLUMES

Different patterns of serum chromogranin
Different patterns of serum chromogranin A in patients with prostate cancer with and without undergoing hormonal therapy
โœ James T. Wu; Tsu-Lan Wu; Christine P.-Y. Chang; Kuo-Chien Tsao; Chien-Feng Sun ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 79 KB ๐Ÿ‘ 2 views

Elevated serum chromogranin A (CgA) levels have been detected in patients with prostate cancer who have developed resistance to hormonal therapy. We would like to reexamine these cases by using serial specimens to determine whether such elevated levels are also detectable in prostate cancer patients

Differences in the recognition of tumor-
Differences in the recognition of tumor-specific CD8+ T cells derived from solid tumor, metastatic lymph nodes and ascites in patients with gastric cancer
โœ Koji Kono; Fumiko Ichihara; Hidehiko Iizuka; Takayoshi Sekikawa; and Yoshirou Ma ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 43 KB ๐Ÿ‘ 1 views

We established gastric cancer-specific CD8 1 T-cell (T CD8 1) lines derived from different lymphocyte sources in the same patients by repeated stimulation with mitomycin-C-treated autologous tumor cells with low-dose interleukin-2, and we compared recognition patterns among the T CD8 1 derived from

Brachytherapy and continuous infusion 5-
Brachytherapy and continuous infusion 5-fluorouracil for the treatment of locally advanced, lymph node negative, prostate cancer: A phase I trial
โœ William A. See; Robert Dreicer; James A. Wheeler; Paula K. Forest; Stefan Loenin ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 405 KB

BACKGROUND. 5-fluorouracil (5-FU) is a known radiosensitizer that enhances efficacy, in vivo and in vitro, when administered during radiotherapy. The following study was performed to evaluate the toxicity of continuous infusion 5-FU administered concomitant with brachytherapy in patients with locall

Immunoreactivity of prostate-specific an
Immunoreactivity of prostate-specific antigen in male breast carcinomas: Two examples of a diagnostic pitfall in discriminating a primary breast cancer from metastatic prostate carcinoma
โœ Raj K. Gupta ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 81 KB ๐Ÿ‘ 2 views

Prostatic-specific antigen (PSA) is regarded as a specific marker secreted by normal and neoplastic acinar epithelial cells of the prostate gland; its detection by immunocytochemistry has been accepted as an indication of metastatic prostate cancer. This is ascribed to the commonly held belief that